Emerging medicine targets AIDS virus in early stages

Published



Drug resistance is the main reason HIV patients have trouble with their medications failing, doctors say, but a local laboratory is breaking ground on a new class of therapeutics called fusion inhibitors, which may attack resistant HIV strains.

Panacos Pharmaceuticals Inc. ? a Gaithersburg biotechnology company developing antiviral therapeutics ? presented its HIV fusion inhibitor program at the XVI International AIDS Conference in Toronto this week.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.